Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Novartis receives EC approval for Jakavi to treat myelofibrosis

Novartis receives EC approval for Jakavi to treat myelofibrosis

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Once-daily Gralise significantly reduces pain intensity in PHN patients

Once-daily Gralise significantly reduces pain intensity in PHN patients

Herpes zoster vaccine recommendations questioned in patients on biologics

Herpes zoster vaccine recommendations questioned in patients on biologics

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Shingles vaccine may not increase risk of varicella in people with auto-immune diseases

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Anti-TNFs increase risk for herpes zoster infections in IRD patients

Rheumatism drugs may increase shingles risk

Rheumatism drugs may increase shingles risk

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

Anti-TNFs increase risk of shingles in patients with inflammatory rheumatic diseases

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

Risk of recurrent shingles episode is relatively low: Study

Risk of recurrent shingles episode is relatively low: Study

Herpes zoster vaccine safe and well tolerated: Study

Herpes zoster vaccine safe and well tolerated: Study

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Merck announces data from ZOSTAVAX Phase III study on shingles

Merck announces data from ZOSTAVAX Phase III study on shingles

New guidelines offer guidance on how and when to switch between RA drug classes

New guidelines offer guidance on how and when to switch between RA drug classes

Europe conference to discuss on new HIV indicator diseases

Europe conference to discuss on new HIV indicator diseases

NEJM publishes results from two Jakafi Phase III studies on MF

NEJM publishes results from two Jakafi Phase III studies on MF

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

Incyte announces further analyses from Jakafi Phase III trial on myelofibrosis

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF